Myasthenia gravis is stratified by antibody subtype, not severity; only the roughly 85% of US patients who are AChR-positive can access C5 inhibitors.

Myasthenia gravis is an autoantibody-mediated disorder of the neuromuscular junction. Antibodies against the acetylcholine receptor, muscle-specific kinase, or LRP4 disrupt signal transmission and produce fluctuating, fatigable weakness. US prevalence is estimated at 100,000 to 200,000 patients, with recognised underdiagnosis. The population divides by serology: roughly 85% are AChR-antibody positive, about 5% MuSK-antibody positive, around 2% LRP4-positive, and 8 to 10% seronegative. Because AChR-mediated disease is complement-driven at the nerve-muscle junction, the C5 inhibitor class is approved only in the AChR-positive subgroup, making serology the commercial gate as much as the clinical one.

Severity is defined by the myasthenic crisis: respiratory failure requiring intubation and ICU support. An estimated 15% to 20% of patients experience at least one crisis in their lifetime, most often triggered by infection, with roughly 4% mortality per episode. Historical series show a median of about 13 days to extubation, with older age and low post-intubation vital capacity predicting a longer ventilator stay. The outstanding evidence gap is comparative effectiveness: which patients benefit most from FcRn blockade, complement inhibition, or traditional immunosuppression remains unresolved.

Antibody serology, not symptom severity, decides who can access which drug class.

Five questions this report answers:

Q1 - What is the AChR / MuSK / LRP4 / seronegative split of US gMG patients?

Q2 - How common and how dangerous is a myasthenic crisis in gMG patients?

Q3 - Where does misdiagnosis concentrate along the US gMG diagnostic pathway?

Q4 - What share of US myasthenia gravis patients are AChR-antibody positive?

Q5 - What triggers a myasthenic crisis, and how often is it fatal?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#MyastheniaGravis #gMG #Neurology #RareDisease #USHealthcare #Autoimmune

Live report page:  https://axlrx.ai/myasthenia-gravis/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/